Poniard Pharmaceuticals, Inc. (PARD)

Poniard Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2010	FY 2009	FY 2008	FY 2007	FY 2006
Period Ending	Sep 30, 2011	Dec 31, 2010	Dec 31, 2009	Dec 31, 2008	Dec 31, 2007	Dec 31, 2006
Selling, General & Admin	14.44	18.43	16.6	16.91	14.43	8.51
Research & Development	-0.12	6.69	24.34	32.25	21.03	12.4
Operating Expenses	14.32	25.12	40.94	49.16	35.46	20.9
Operating Income	-14.32	-25.12	-40.94	-49.16	-35.46	-20.9
Interest Expense	-0.54	-2.21	-3.14	-1.9	-1.73	-
Interest & Investment Income	0.01	0.12	0.41	2.49	4.3	-
Other Non Operating Income (Expenses)	0.01	-	-	-	-	-2.06
EBT Excluding Unusual Items	-14.83	-27.21	-43.67	-48.57	-32.89	-22.96
Merger & Restructuring Charges	-	-1.63	-0.47	-	-	-
Gain (Loss) on Sale of Investments	0.01	-	-	-	-	-
Gain (Loss) on Sale of Assets	-	-	-	-	0.11	0.07
Asset Writedown	-	-	-2.07	-	-	-0.4
Other Unusual Items	-1.22	-1.22	0.5	-	-	-
Pretax Income	-16.04	-30.05	-45.72	-48.57	-32.78	-23.29
Earnings From Continuing Operations	-16.04	-30.05	-45.72	-48.57	-32.78	-23.29
Net Income	-16.04	-30.05	-45.72	-48.57	-32.78	-23.29
Preferred Dividends & Other Adjustments	0.19	0.74	0.5	0.5	0.5	0.5
Net Income to Common	-16.23	-30.79	-46.22	-49.07	-33.28	-23.79
Shares Outstanding (Basic)	4	4	1	1	1	0
Shares Outstanding (Diluted)	4	4	1	1	1	0
Shares Change (YoY)	289.32%	368.30%	1.69%	12.76%	77.04%	209.68%
EPS (Basic)	-3.79	-7.46	-52.41	-56.58	-43.28	-54.77
EPS (Diluted)	-3.79	-7.46	-52.41	-56.58	-43.28	-54.77
Free Cash Flow	-10.47	-24.28	-35.51	-33.88	-25.43	-17.66
Free Cash Flow Per Share	-2.44	-5.88	-40.27	-39.07	-33.06	-40.65
EBITDA	-13.04	-23.8	-39.47	-47.55	-33.93	-20.3
D&A For EBITDA	1.28	1.31	1.47	1.6	1.53	0.61
EBIT	-14.32	-25.12	-40.94	-49.16	-35.46	-20.9

Updated Oct 28, 2011. Source: S&P Global Market Intelligence. Standard template. Financial Sources.